Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEHP.L Share News (EHP)

  • There is currently no data for EHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Nautical Petroleum, ThirdForce, Allied Gold...

Mon, 09th Nov 2009 11:43

Oil group Nautical Petroleum reported 'significant progress' in its asset portfolio in the year to June 30 and said it expects its assets to rise in value once they move into the execution stage.Pre-tax losses for the year totalled £6.63m, compared with £4.52m the previous year.Shares in e-learning software group ThirdForce jumped after its chief executive and chairman made a formal offer for the company.The directors, who have set up an investment vehicle called LearnVantage, offered shareholders one LearnVantage share for every ThirdForce share, three LearnVantage shares plus €0.12 for every four ThirdForce shares or €0.105 for every ThirdForce share.Allied Gold's takeover offer for Australian Solomons Gold has gone unconditional, giving the miner 49% of the business.Those ASG shareholders who accepted the offer will get 0.85 Allied shares for every ASG share held. Allied expects further acceptances."This is a milestone in Allied Gold's emergence as a substantial South East Asian gold producer with a clear production development profile that will see the company producing in excess of 250,000 oz of gold," said Allied's executive chairman, Mark Caruso. Greystar Resources, which owns the Angostura gold-silver deposit in northeastern Colombia, is to start two exploration drill programs to investigate near surface oxide gold mineralization recently discovered at the Mongora prospect.The first drill holes will target the Los Laches area at Angostura where previously drilled core holes LL08-24 and QP08-03 returned "excellent" results.Uruguay Mineral Exploration and Canada's Fortune Valley Resources have completed their merger, creating a more significant Latin American focused gold producer.Mixed phase catalyst technology developer Catalytic Solutions saw its pre-tax loss narrow to $7.94m in the first half of 2009 from $9.92m a year earlier on revenue that grew from $26.83m to $27.65m.The company's shares remain suspended while it tackles its liquidity crisis. The company is in talks over short-term financing to give it breathing space to sort out longer term facilities.Electronic payments company Earthport said its services are gaining popularity among Exchange Houses in the United Arab Emirates (UAE). Earthport is the exclusive provider of 'to bank' remittance services in 119 Exchange House branches in the UAE, and expects to see further adoption of the service before the end of the year in the UAE, Kuwait, Oman and Jordan.Shares in ReGen Therapeutics were wanted after the pharma company announced more good news relating to its Zolpidem project, Results of tests conducted in South Africa indicate that zolpidem significantly boosts the cognitive and motor performance of brain damage victims.Drug testing group Epistem is to present the clinical results of two recently completed studies on hair follicle analysis at the AACR-NCI-EORTC conference in Boston next week.The first study demonstrates androgen receptor pathway activity in hair from elderly volunteers, while in the second, a phase I study, novel pharmacodynamic markers for Enzon Pharmaceuticals Inc's survivin messenger ribonucleic acid (mRNA) antagonist were identified from hair follicle analysis. Dr. Ged Brady will present data which demonstrates plucked human scalp hairs as a preferred method for assessing androgen receptor directed therapies, the company said.Tristel, which provides infection and contamination control products, has raised £2m through a placing.It will use the funds to accelerate expansion of its overseas businesses, the company said.
More News
7 Dec 2012 15:22

Epistem to raise 4.3m pounds via placing

Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share. The new ordinary shares, which represent 8.9% of Epistem's issued share capital have been conditionally placed with existing and new i

Read more
24 Oct 2012 15:32

Investec invests in Epistem

Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine. Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%. Earlier this month it reported steady full-year results, while d

Read more
16 Oct 2012 08:07

Epistem delivers steady performance

Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes. Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine d

Read more
6 Aug 2012 08:59

Epistem secures contract for TB test

EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts. The firm also said it has reached agreement with US firm Becton Dickinson for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis usin

Read more
5 Jul 2012 10:42

Small caps round-up: Epistem, Stadium Group, Trading Emissions

Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for Indi

Read more
11 Oct 2011 08:44

Big things expected of EpiStem's Genedrive device

Epistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year. Revenue in the year to June 30th edged up to £5.75m from £5.74m the year before, while profit on ordinary activities before ta

Read more
29 Mar 2011 13:23

Epistem sees solid growth

Adult stem cell specialist Epistem scraped into profit in the first half of its financial year. The company, which made its maiden full year profit last year, saw profit before tax in the six months to the end of December rise to £0.1m from £5,000 in the corresponding period of 2009. Revenue rose

Read more
5 Oct 2010 13:28

Maiden pre-tax profit for Epistem

UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007. The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all di

Read more
29 Jul 2010 14:16

Small caps: Titon, Utd Drug, Vernalis...

Blinds specialist Titon's revenues for the 3 months to June were 19% higher than the corresponding period last year, with UK sales 15% higher and the rest of the world 37% higher. Growth in the UK came from higher sales of mechanical ventilation systems. There were also increased sales volumes in

Read more
29 Jul 2010 07:38

Epistem FY Trading In line With Market Views, Sees Pretax Profit Up

LONDON (Dow Jones)--Epistem Holdings PLC (EHP.LN), a biotechnology company, said Thursday that trading over the year was in line with market forecasts and the company expects to report growth in year on year after tax profit. -Shares closed Wednesday at 360 pence, valuing the company at GBP28.36

Read more
9 Mar 2010 12:03

EpiStem breaks even as revenue soars

The Novel Therapies division is threatening to steal the show at epithelial stem cells specialist Epistem, as the benefits of its transformational deal with Swiss pharmaceutical giant Novartis kicks in. The UK biotechnology company saw revenue soar 90% in 2009 almost entirely as a result of the co

Read more
12 Oct 2009 17:18

Douglas sure about Shore

Shares in stockbroker Shore Capital have almost tripled in value since April, but non-executive director Barclay Douglas thinks there's more to come. The accountant has spent £92,000 on 250,000 shares at 36.75p each. He now owns 1.25m shares, or half a per cent of the company. Shore received a sho

Read more
6 Oct 2009 11:37

Update: Epistem benefits from raised profile

Drug testing group Epistem moved closer to profit after a research and collaboration deal with the Swiss pharmaceutical giant Novartis helped revenues soar. The firm posted a pre-tax loss of £700,000 in the year to June 30 compared with losses of £1.3m previously, with revenues nearly doubling to £

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.